Bridgewater Associates LP Makes New $638,000 Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bridgewater Associates LP purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,245 shares of the biotechnology company’s stock, valued at approximately $638,000.

Several other institutional investors have also modified their holdings of the company. Manchester Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the 4th quarter worth $36,000. Steward Partners Investment Advisory LLC boosted its position in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 95.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 216 shares during the period. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SRPT. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Needham & Company LLC dropped their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday, April 3rd. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $161.83.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $53.79 on Friday. The firm has a 50 day simple moving average of $82.21 and a 200 day simple moving average of $107.78. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25. The stock has a market cap of $5.22 billion, a P/E ratio of 43.03 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.